GT BIOPHARMA INC. DL-,001
GT BIOPHARMA INC. DL-,001
Share · US36254L3087 · GTBP · A402U5 (XNCM)
Overview Financial Indicators
2,57 EUR
-3,60 % -0,10 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
10.06.2025 18:15

Current Prices from GT BIOPHARMA INC. DL-,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
GTBP
USD
10.06.2025 18:15
2,94 USD
3,01 USD
-2,32 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-3,79 % 17,59 % 26,80 % 16,19 % 0,96 % -12,35 % -97,39 %

Company Profile for GT BIOPHARMA INC. DL-,001 Share

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Company Data

Name GT BIOPHARMA INC. DL-,001
Company GT Biopharma, Inc.
Symbol GTBP
Website https://www.gtbiopharma.com
Primary Exchange XNCM Frankfurt
WKN A402U5
ISIN US36254L3087
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Mr. Michael Martin Breen L.L.B.
Country United States of America
Currency EUR
Employees 0,0 T
Address 8000 Marina Boulevard, 94005 Brisbane
IPO Date 2018-03-27

Ticker Symbols

Name Symbol
Frankfurt OXIA.F
NASDAQ GTBP

More Shares

Investors who GT BIOPHARMA INC. DL-,001 hold also have the following shares in their portfolio:
GR.C.P.FIN. 24/UND. FLR
GR.C.P.FIN. 24/UND. FLR Bond
HARTFORD FINANCIAL SERVICES GROUP INC
HARTFORD FINANCIAL SERVICES GROUP INC Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025